Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Hepatitis B Virus (HBV)-Specific T Cell Receptor (TCR)-T Cell Therapy Combined With Nucleos(t)Ide Analogues (NAs) in HBeAg-Positive Chronic Hepatitis B Patients

NCT06885710 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT06885710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06885710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Hepatitis B Virus (HBV)-Specific T Cell Receptor (TCR)-T Cell Therapy Combined With Nucleos(t)Ide Analogues (NAs) in HBeAg-Positive Chronic Hepatitis B Patients
Lead sponsor
Changhai Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 31, 2024
Completion date
December 1, 2028
Enrollment
19 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b